Olivia Newton-John Cancer Research Institute
13
1
5
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
7.7%
1 terminated/withdrawn out of 13 trials
75.0%
-11.5% vs industry average
8%
1 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer
Role: collaborator
Vorasidenib Maintenance for IDH Mutant Astrocytoma
Role: collaborator
Combination Immunotherapy in Rare Cancers Under InvesTigation
Role: lead
Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.
Role: lead
Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy
Role: lead
A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers
Role: lead
A Trial of Radiotherapy and Durvalumab in DLBCL and FL
Role: collaborator
A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)
Role: lead
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
Role: collaborator
Medical Imaging of Cachexia
Role: lead
Bioimaging Study of 89Zr-M7824 in NSCLC
Role: lead
A Trial of KB004 in Patients With Glioblastoma
Role: lead
Pembrolizumab + CVA21 in Advanced NSCLC
Role: lead
All 13 trials loaded